The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition
Open accessAbstract
Snail1 is a zinc finger transcriptional repressor whose pathological expression has been linked to cancer cell epithelial–mesenchymal transition (EMT) programs and the induction of tissue-invasive activity, but pro-oncogenic events capable of regulating Snail1 activity remain largely uncharacterized. Herein, we demonstrate that p53 loss-of-function or mutation promotes cancer cell EMT by de-repressing Snail1 protein expression and activity. In the absence of wild-type p53 function, Snail1-dependent EMT is activated in colon, breast, and lung carcinoma cells as a consequence of a decrease in miRNA-34 levels, which suppress Snail1 activity by binding to highly conserved 3′ untranslated regions in Snail1 itself as well as those of key Snail1 regulatory molecules, including β-catenin, LEF1, and Axin2. Although p53 activity can impact cell cycle regulation, apoptosis, and DNA repair pathways, the EMT and invasion programs initiated by p53 loss of function or mutation are completely dependent on Snail1 expression. These results identify a new link between p53, miR-34, and Snail1 in the regulation of cancer cell EMT programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Likewise, p53 loss-of-function or mutation occur frequently as a later event in cancer progression (Vogelstein et al., 2000), which suggests that the acquisition of invasive activity occurs in conjunction with additional oncogenic events, particularly in p53 wt versus p53-null cancer cells (Fig.”
BackgroundThe E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Cited by
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
Epithelial Mesenchymal Transition in Tumor Metastasis
Mittal, V. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043854 · Cited by 1,528
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
Epithelial–mesenchymal plasticity in carcinoma metastasis
Tsai, J. H., & Yang, J. (2013) · Genes & Development · doi:10.1101/gad.225334.113 · Cited by 1,136
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Epithelial–Mesenchymal Plasticity: A Central Regulator of Cancer Progression
Ye, X., & Weinberg, R. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.012 · Cited by 1,013
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
EMT, cell plasticity and metastasis
Chaffer, C. L., San Juan, B. P., Lim, E., & Weinberg, R. A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9648-7 · Cited by 861
Grande, M. T., Sánchez-Laorden, B., López-Blau, C., De Frutos, C. A., Boutet, A., Arévalo, M., Rowe, R. G., Weiss, S. J., López-Novoa, J. M., & Nieto, M. A. (2015) · Nature Medicine · doi:10.1038/nm.3901 · Cited by 783
Self-citationIL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753
“Furthermore, we and others have recently shown that SNAIL, another well-established inducer of EMT, is a direct target of miR-34a (18, 19).”
BackgroundTumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
Jolly, M. K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00155 · Cited by 693
A network-biology perspective of microRNA function and dysfunction in cancer
Bracken, C. P., Scott, H. S., & Goodall, G. J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.134 · Cited by 668
To differentiate or not — routes towards metastasis
Brabletz, T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3265 · Cited by 623
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness
Sánchez-Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 518
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
EMT as the ultimate survival mechanism of cancer cells
Tiwari, N., Gheldof, A., Tatari, M., & Christofori, G. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.013 · Cited by 512
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 510
Drug Resistance Driven by Cancer Stem Cells and Their Niche
Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., & Ochiya, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122574 · Cited by 508
GSK-3 as potential target for therapeutic intervention in cancer
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2037 · Cited by 508
MicroRNA-based regulation of epithelial–hybrid–mesenchymal fate determination
Lu, M., Jolly, M. K., Levine, H., Onuchic, J. N., & Ben-Jacob, E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318192110 · Cited by 487
Kaufhold, S., & Bonavida, B. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/preaccept-1929235422128885 · Cited by 469
Zhang, J., Tian, X.-J., Zhang, H., Teng, Y., Li, R., Bai, F., Elankumaran, S., & Xing, J. (2014) · Science Signaling · doi:10.1126/scisignal.2005304 · Cited by 462
The Role of miRNAs in Regulating Gene Expression Networks
Gurtan, A. M., & Sharp, P. A. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.007 · Cited by 443
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer Patients
Kang, Y., & Pantel, K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.017 · Cited by 421
The p53/miR-34 axis in development and disease
Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju003 · Cited by 354
Multilayer control of the EMT master regulators
Zheng, H., & Kang, Y. (2014) · Oncogene · doi:10.1038/onc.2013.128 · Cited by 346
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
p53 and Tumor Suppression: It Takes a Network
Boutelle, A. M., & Attardi, L. D. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.12.011 · Cited by 317
p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling
Kim, N. H., Kim, H. S., Kim, N.-G., Lee, I., Choi, H.-S., Li, X.-Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001744 · Cited by 308
Self-citationMicroenvironmental Regulation of Epithelial–Mesenchymal Transitions in Cancer
Gao, D., Vahdat, L. T., Wong, S., Chang, J. C., & Mittal, V. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1223 · Cited by 305
Wu, Z.-Q., Li, X.-Y., Hu, C. Y., Ford, M., Kleer, C. G., & Weiss, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205822109 · Cited by 305
Self-citationA positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
Okada, N., Lin, C.-P., Ribeiro, M. C., Biton, A., Lai, G., He, X., Bu, P., Vogel, H., Jablons, D. M., Keller, A. C., et al. (2014) · Genes & Development · doi:10.1101/gad.233585.113 · Cited by 297
Tian, X.-J., Zhang, H., & Xing, J. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2013.07.011 · Cited by 281
Cancer stem cells: A review from origin to therapeutic implications
Atashzar, M. R., Baharlou, R., Karami, J., Abdollahi, H., Rezaei, R., Pourramezan, F., & Zoljalali Moghaddam, S. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29044 · Cited by 281
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Nieto, M. A., & Cano, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.05.003 · Cited by 262
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
Agostini, M., & Knight, R. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1825 · Cited by 254
The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer
Peng, Y., Zhang, X., Feng, X., Fan, X., & Jin, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.12923 · Cited by 149
“miR-34 WNT1/3, β-catenin, LRP6, LEF1, AXIN2,TCF7 Tumor suppressor Lung cancer, Breast cancer, CRC, Prostate cancer, HCC [55, 57-59, 119, 134]”
BackgroundThe Roles of MicroRNAs in Breast Cancer
Takahashi, R.-U., Miyazaki, H., & Ochiya, T. (2015) · Cancers · doi:10.3390/cancers7020598 · Cited by 116
The comprehensive landscape of miR-34a in cancer research
Li, S., Wei, X., He, J., Cao, Q., Du, D., Zhan, X., Zeng, Y., Yuan, S., & Sun, L. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09973-3 · Cited by 84
The emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38
Metadata
- Authors
- Kim, N. H., Kim, H. S., Li, X.-Y., Lee, I., Choi, H.-S., Kang, S. E., Cha, S. Y., Ryu, J. K., Yoon, D., Fearon, E. R., Rowe, R. G., Lee, S., Maher, C. A., Weiss, S. J., & Yook, J. I.
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2011-10-24
- Volume
- 195
- Issue
- 3
- Pages
- 417-433
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- OpenAlex
- W2155487079
- Cited by
- 432
- References
- 73
- FWCI
- 13.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.